Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease. NOTE: Patients with Her-2 positive (3+ by IHC or gene amplification by FISH) are eligible only if they have had prior trastuzumab therapy.~* Must have measurable or non-measurable lesions as defined by the Response Evaluation Criteria in Solid Tumors (RECIST).~* Two or fewer prior chemotherapy regimens in any disease setting. NOTE: All adjuvant and neoadjuvant chemotherapy will be considered one regimen. NOTE: Prior hormonal therapy for metastatic disease is allowed. NOTE: Prior radiation therapy is allowed as long as the irradiated area is not the only source of evaluable disease.~* Age \> 18 years at the time of consent.~* Written informed consent and HIPAA authorization for release of personal health information.~* Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.~* Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy.~* Ability to comply with study and/or follow-up procedures.~Exclusion Criteria:~* No prior therapy with bevacizumab, sorafenib or any other known VEGF inhibitors.~* No known hypersensitivity to any component of the study drugs.~* No other forms of cancer therapy including radiation, chemotherapy and hormonal therapy within 21 days prior to being registered for protocol therapy.~* No history or radiologic evidence of CNS metastases including previously treated, resected, or asymptomatic brain lesions or leptominigeal involvement. A head CT or MRI must be obtained within 28 days prior to being registered for protocol therapy.~* No other participation in another clinical drug study within 28 days prior to being registered for protocol therapy.~* No known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C~* No major surgical procedure within 28 days prior to being registered for protocol therapy or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device and breast biopsy will not be considered major surgery.~* No minor surgical procedure within 7 days prior to being registered for protocol therapy.~* No known history of cerebrovascular disease including TIA, stroke or subarachnoid hemorrhage.~* No known history of ischemic bowel.~* No known history of deep venous thrombosis or pulmonary embolism.~* No history of hypertensive crisis or hypertensive encephalopathy.~* No non-healing wound or fracture.~* No active infection requiring parenteral antibiotics.~* No other hemorrhage/bleeding event ≥ CTCAE grade 3 within 28 days prior to being registered for protocol therapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm A (Type: EXPERIMENTAL): Sorafenib 200mg po daily, Bevacizumab 5mg/kg every other week, 1 Cycle = 4 weeks. Imaging every third cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues